Assignee
WELLMARKER BIO CO LTD
KR·3 granted patents·12 pending applications·1 citations·filing 2015–2022
Top patents by PatentIndex Score
15 records- 0169US11447500B2Thienopyridine derivatives and pharmaceutical composition comprising sameWELLMARKER BIO CO LTD·Filed 2019·Granted Sep 20, 2022·1 cites·15 claims
- 0262US2021292848A1Novel biomarker for predicting sensitiviy to egfr-targeting agent, and use thereofWELLMARKER BIO CO LTD·Filed 2021·Application pending·0 cites
- 0362US2021292849A1Novel biomarker for predicting sensitivity to egfr-targeting agent, and use thereofWELLMARKER BIO CO LTD·Filed 2021·Application pending·0 cites
- 0453US2022288043A1Thienopyridine derivatives and pharmaceutical composition comprising sameWELLMARKER BIO CO LTD·Filed 2022·Application pending·0 cites
- 0550US2023346790A1Pharmaceutical composition for prevention or treatment of cancers associated with kras mutationWELLMARKER BIO CO LTD·Filed 2021·Application pending·0 cites
- 0649US2023241073A1Pharmaceutical composition for preventing or treating non-small cell lung cancer associated with ron mutantation, and method using sameWELLMARKER BIO CO LTD·Filed 2021·Application pending·0 cites
- 0749US2024262906A1Anti-igsf1 antibody and use thereofWELLMARKER BIO CO LTD·Filed 2021·Application pending·0 cites
- 0849US2023099204A1Pharmaceutical composition for prevention or treatment of cancer in which kras mutation and activated ron are presentWELLMARKER BIO CO LTD·Filed 2021·Application pending·0 cites
- 0948US2023172914A1Biomarker-based therapeutic compositionWELLMARKER BIO CO LTD·Filed 2019·Application pending·0 cites
- 1048US2023202992A1Pharmaceutical composition for preventing or treating small-cell lung cancer associated with ron mutants and method using sameWELLMARKER BIO CO LTD·Filed 2021·Application pending·0 cites
- 1148US2024245692A1Pharmaceutical composition for preventing or treating ron-mutation-associated biliary tract cancerWELLMARKER BIO CO LTD·Filed 2022·Application pending·0 cites
- 1245US11186873B2Combination method for treating cancer by targeting immunoglobulin superfamily member 1 (IGSF1) and mesenchymal-epithelial transition factor (MET)WELLMARKER BIO CO LTD·Filed 2015·Granted Nov 30, 2021·0 cites·15 claims
- 1345US2022235064A1Oxo-pyridine fusion ring derivative and pharmaceutical composition comprising sameWELLMARKER BIO CO LTD·Filed 2020·Application pending·0 cites
- 1445US2023242521A1Pharmaceutical composition for preventing or treating pancreatic cancer associated with ron mutation and method using sameWELLMARKER BIO CO LTD·Filed 2021·Application pending·0 cites
- 1534US11946934B2Biomarker for predicting the sensitivity to a protein kinase inhibitor and a use thereofWELLMARKER BIO CO LTD·Filed 2015·Granted Apr 2, 2024·0 cites·3 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →